Vericel Corp
About Vericel Corp
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $276.3M
- Net income
- $16.5M
- Total assets
- $488.0M
- Market cap
- $1.9B
- Gross margin
- 74.4%
- Operating margin
- 4.0%
- Net margin
- 6.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $276.3M
- Cost of revenue
- $70.7M
- Gross profit
- $205.6M
- Operating expenses
- $194.6M
- Operating income
- $11.0M
- Income tax
- $859.0K
- Net income
- $16.5M
- EPS (basic)
- $0.33
- EPS (diluted)
- $0.32
Balance sheet
- Total assets
- $488.0M
- Current assets
- $247.4M
- Total liabilities
- $133.3M
- Current liabilities
- $49.1M
- Shareholders’ equity
- $354.6M
Cash flow
- Operating cash flow
- $51.9M
- Investing cash flow
- -$43.9M
- Financing cash flow
- $7.1M
- Net cash flow
- $15.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- P/E ratio
- 111.8
- EPS (diluted)
- $0.32
- Shares outstanding
- 51.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $16.5M in FY2025.
- Revenue grew 77% from FY2021 to FY2025.
- Gross margin of 74.4%, net margin 6.0%.
- Trading 22% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 111.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vericel Corp.
Write a review
News about Vericel Corp
News & sentiment via Polygon.io
